Long-term follow-up of the ASPREE trial in 19,114 older adults (median 8.6 years): low-dose aspirin was not associated with overall cancer incidence (HR 0.98) or colorectal cancer (HR 1.01), but was associated with higher cancer mortality (HR 1.15).
RCTn = 19,114
Orchard et al. Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE Trial